NASDAQ · HALO

Halozyme Therapeutics, Inc.

$81.48 -$0.45 (-0.55%) 1D Pre-market
Charting by TradingView

Key Metrics

$9.72B
Market cap
27.86×
P/E · TTM
$1.51B
Revenue · TTM
$348.84M
Net income
EPS · TTM $2.75
Dividend yield —
Free cash flow $667.65M
Beta · 1Y 0.53
EBITDA · TTM $516.30M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 18
    The stock moved -9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 18

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$9.72B
Enterprise value$11.55B
Shares outstanding118.6M
52-wk range$57.68 – $83.50
Avg volume · 20D1.4M
Net cash −$1.83B
Book value / share$1.73
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Halozyme Therapeutics, Inc.
IPO dateMar 12, 2004
Employees423

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E27.86
P/S6.44
P/FCF14.56
EV/EBITDA22.38
EV/Sales7.66
Graham №$10.37

Profitability

Gross —
Operating 33.4%
Net 23.1%
FCF 44.3%
ROE / ROIC 119.6% · 17.0%

Financial Health

Current ratio2.76
Quick ratio2.33
Debt / equity9.76
Debt / EBITDA 4.15
Net cash −$1.83B
Working capital$639.83M

Cash Flow · TTM

Operating CF $677.42M
Capex −$9.76M
Free cash flow $667.65M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

4.0
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$10.37 vs $81.48
Trades 7.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings